Celltrion acquires approval of ‘Herzuma’ in Europe
Celltrion announced Herzuma(CT-P6, generic name: Trastuzumab), an antibody biosimilar for the treatment of breast cancer, acquired approval from the European Medicines Agency(EMA) on the 13th(local time). The EMA gave the approval for the Herzuma’s entire indications, such as early breast cancer ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
